To further exploit the potential of the triple C2 variant to maximize CDC at a limited concentration of anti-CD20 mAbs, we examined sera from five NHL patients treated with rituximab, which were collected before the second, third, and fourth infusions of the drug administered in four-week intervals. Here, MS4A1 is linked to non-Hodgkin lymphoma.